EGFR and adenocarcinoma: As has been described, EGFR-TKIs are not universally effective for lung cancer, but these drugs are effective in patients who have particular clinical or biological characteristics, for example, Asian, nonsmoking female patients with adenocarcinomas with EGFR mutations.